BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Esperion Therapeutics, Inc. 

3621 S. State Street
695 KMS Place
Ann Arbor  Michigan  48108  U.S.A.
Phone: 734-332-0506 Fax: 734-332-0516


SEARCH JOBS
Esperion Therapeutics, Inc., is a biopharmaceutical company dedicated to the discovery, development and commercialization of a novel class of therapies to treat cardiovascular and metabolic diseases, including atherosclerosis, as they relate to high density lipoprotein cholesterol, "HDL-C", also known as the "good" cholesterol.

The technology platform for Esperion is based upon the Reverse Lipid Transport (RLT) pathway. The RLT pathway is responsible for removing excess cholesterol and other lipids from arterial walls and other tissues for transport to the liver and elimination from the body. The Company's product candidates work by stimulating the RLT pathway through the enhancement of key HDL properties, which may result in improved vascular structure and function. Esperion is focusing its efforts on developing both acute and chronic therapies for cardiovascular and metabolic diseases.

Esperion was founded in 1998 by, among others, members of the Warner-Lambert/Parke-Davis (now Pfizer) team that discovered and developed atorvastatin, the highly successful multibillion-dollar drug. Since that time, an additional group of exceptional scientists and specialists has joined the Company. Many of these individuals have been instrumental in the discovery, development and commercialization of several of the pharmaceutical industry's most successful therapies. It is this combined team that makes Esperion a leading enterprise in HDL drug discovery and research.

Key Management:

  • Roger Newton, Ph.D.
    President and CEO
  • Timothy Mayleben
    Chief Operating Officer and CFO

    Last Updated: 01-18-05

     Key Statistics


    Email: info@esperion.com
    Ownership: Public

    Web Site: Esperion Therapeutics, Inc.
    Employees:
    Symbol: ESPR
     



  • Industry
    Biotechnology






     Company News
    Esperion Therapeutics, Inc. (ESPR) To Present At Biocentury Future Leaders In The Biotech Industry Conference 3/24/2014 9:31:37 AM    More...
    Esperion Therapeutics, Inc. (ESPR) Provides ETC-1002 Program Update; Reports Fourth Quarter And Full Year 2013 Financial Results 3/6/2014 7:18:09 AM    More...
    Esperion Therapeutics, Inc. (ESPR) To Provide ETC-1002 Program Update; Fourth Quarter And Full Year 2013 Financial Results 2/27/2014 8:21:18 AM    More...
    Esperion Therapeutics, Inc. (ESPR) Names Mark E. McGovern, M.D., FACC, FACP, Director 2/13/2014 10:01:19 AM    More...
    Esperion Therapeutics, Inc. (ESPR) Announces The Appointment Of Antonio M. Gotto Jr., M.D., Dphil, As Director 1/13/2014 7:20:36 AM    More...
    Esperion Therapeutics, Inc. (ESPR) Added To The NASDAQ Biotechnology Index 12/27/2013 8:34:02 AM    More...
    Esperion Therapeutics, Inc. (ESPR) Presents Full Results Of Phase 2 Clinical Study Demonstrating That ETC-1002 Lowered LDL-C By An Average Of 32 Percent And Was Well Tolerated In Patients With Hypercholesterolemia And History Of Statin Intolerance 11/18/2013 10:08:53 AM    More...
    Esperion Therapeutics, Inc. (ESPR) Presents Full Results Of Phase 2 Clinical Study Demonstrating That ETC-1002 Lowered LDL-C By An Average Of 32 Percent And Was Well Tolerated In Patients With Hypercholesterolemia And History Of Statin Intolerance 11/18/2013 6:57:32 AM    More...
    Esperion Therapeutics, Inc. (ESPR) Announces Oral Presentation On ETC-1002 At 2013 Scientific Sessions Of The American Heart Association 11/12/2013 10:12:35 AM    More...
    Esperion Therapeutics, Inc. (ESPR) Reports Third Quarter 2013 Financial Results and Provides Development Program Updates 11/7/2013 8:00:42 AM    More...
    123456

    //-->